Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esterified estrogens + methyltestosterone is a combination oral medication containing two hormones—esterified estrogens (a mixture of synthetic estrogen compounds) and methyltestosterone (a synthetic androgen). It is primarily used for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women who do not achieve adequate relief from estrogen therapy alone. The drug works by supplementing declining endogenous hormone levels during menopause to alleviate symptoms such as hot flashes and vaginal dryness. Esterified estrogens act as agonists at the estrogen receptor to restore estrogenic activity in target tissues. Methyltestosterone acts as an agonist at the androgen receptor to provide additional hormonal support that may further reduce menopausal symptoms[1][2][4][5]. This combination product has been marketed under several brand names but has been discontinued or restricted in some markets due to safety concerns related to long-term use of combined sex hormones. It is available only by prescription and should be used for the shortest duration necessary[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esterified estrogens + methyltestosterone.